BNP Paribas Asset Management’s KYTHERA BIOPHARMACEUTICALS, INC COM KYTH Stock Holding History

BNP Paribas Asset Management’s Portfolio KYTH Stock Details KYTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-76,555	Closed	-$3.84M	–	1107
2015 Q1	$3.84M	Sell	76,555 -6,517	-8%	-$274K	0.03%	553
2014 Q4	$2.88M	Sell	83,072 -4,045	-5%	-$141K	0.02%	544
2014 Q3	$2.85M	Buy	87,117 +5,073	+6%	+$179K	0.02%	548
2014 Q2	$3.15M	Buy	82,044 +3,802	+5%	+$133K	0.02%	555
2014 Q1	$3.11M	Sell	78,242 -2,054	-3%	-$91.9K	0.02%	539
2013 Q4	$2.99M	Buy	+80,296	New	+$3.33M	0.02%	542

Other funds holding KYTH

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BNP Paribas Asset Management's KYTH Position: Q2 2015 in Review

BNP Paribas Asset Management sold out of KYTHERA BIOPHARMACEUTICALS, INC COM (KYTH) in Q2 2015, closing a stake of 76,555 shares — an estimated $3.84M sold.

BNP Paribas Asset Management first reported a position in KYTH in Q4 2013 and held it in 6 quarters. The position peaked at $3.84M in Q1 2015. 153 funds tracked by Wall St. Rank hold KYTH as of Q2 2015.

BNP Paribas Asset Management reported no remaining KYTHERA BIOPHARMACEUTICALS, INC COM position as of Q2 2015 after selling out during the quarter.
BNP Paribas Asset Management sold 76,555 KYTHERA BIOPHARMACEUTICALS, INC COM shares in Q2 2015, an estimated $3.84M.
BNP Paribas Asset Management first reported a position in KYTHERA BIOPHARMACEUTICALS, INC COM in Q4 2013 and held it in 6 quarters.
BNP Paribas Asset Management's KYTHERA BIOPHARMACEUTICALS, INC COM position peaked at $3.84M in Q1 2015.
153 funds tracked by Wall St. Rank held KYTHERA BIOPHARMACEUTICALS, INC COM as of Q2 2015.

Based on BNP Paribas Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.